



### **CPT® Category I Vaccine Codes**

The FDA approval pending indicator (↗) was removed from code 90670 following AMA's receipt of notification on February 23, 2010 that this product has achieved FDA approval status.

This revision is effective February 23, 2010, although it will not appear in the printed copy of CPT until the publication of the CPT 2011 codebook.

●90670 Pneumococcal conjugate vaccine, 13 valent, for intramuscular use	<b>Published in CPT 2010 codebook</b>
---	---------------------------------------

Code 90644 was accepted at the June 2009 CPT Editorial Panel meeting for the 2011 CPT book production cycle. This code will not appear in the 2010 CPT codebook. However, due to the Category I vaccine product codes early release policy, this code is effective on January 1, 2010, following the six month implementation period which began July 1, 2009.

↗●90644 Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza b vaccine, tetanus toxoid conjugate (Hib-MenCY-TT), 4 dose schedule, when administered to children 2-15 months of age, for intramuscular use	<b>Released July 1, 2009 Implementation January 1, 2010</b>	<b>CPT 2011</b>
---	---	-----------------

Code 90663 was revised for the sole use of reporting the H1N1 influenza virus, and a new code, 90470 was approved for the specific administration of the H1N1 vaccine by any route. Both of these changes were published on the AMA's Web site on September 28, 2009, for immediate use (<http://www.ama-assn.org/ama/pub/h1n1/resources/cpt-codes.shtml>) along with instructions for the use of NDC codes to assist in tracking of the specific product administered (eg, nasal, IM, IM without preservative) as recommended by the Vaccine Coding Caucus (VCC) (see AMA fact sheet <http://www.ama-assn.org/ama1/pub/upload/mm/362/ama-fact-sheet-h1n1-reporting.pdf>).

This revision is effective September 28, 2009, although it will not appear in the printed copy of CPT until the publication of the CPT 2011 codebook.

<p>▲ 90663 Influenza virus vaccine, pandemic formulation, <u>H1N1</u></p> <p>● 90470 H1N1 immunization administration (intramuscular, intranasal), including counseling when performed</p>	<p><b>Published on AMA's website effective September 28, 2009</b></p>
--	---

The FDA approval pending indicator (↗) was removed from code 90650 following communication that this product achieved FDA approval status on October 16, 2009.

This revision is effective October 16, although it will not appear in the printed copy of CPT until the publication of the CPT 2011 codebook.

<p>▲ 90650 Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use</p>	<p><b>Published on AMA's website effective October 16, 2009.</b></p>
--	--

The FDA approval pending indicator (↗) was removed from code 90662 following notification that this product achieved FDA approval status on December 23, 2009.

This revision is effective December 23<sup>rd</sup>, although it will not appear in the printed copy of CPT until the publication of the CPT 2011 codebook.

<p>▲ 90662 Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use</p>	<p><b>Published on AMA's website effective December 23, 2009.</b></p>
--	---

Codes 90664, 90666, 90667, 90668 were accepted at the October 2009 CPT Editorial Panel meeting for the 2011 CPT book production cycle. These codes will not appear in the 2010 CPT codebook. However, due to the Category I vaccine product codes early release policy, these code are effective on July 1, 2010, following the six month implementation period which began January 1, 2010.

●90664	Influenza virus vaccine, pandemic formulation, live, for intranasal use	<b>Released January 1, 2010 Implementation July 1, 2010</b>	<b>CPT 2011</b>
●90666	Influenza virus vaccine, pandemic formulation, split virus, preservative free, for intramuscular use	<b>Released January 1, 2010 Implementation July 1, 2010</b>	<b>CPT 2011</b>
●90667	Influenza virus vaccine, pandemic formulation, split virus, adjuvanted, for intramuscular use	<b>Released January 1, 2010 Implementation July 1, 2010</b>	<b>CPT 2011</b>
●90668	Influenza virus vaccine, pandemic formulation, split virus, for intramuscular use	<b>Released January 1, 2010 Implementation July 1, 2010</b>	<b>CPT 2011</b>

↗ = FDA approval pending ● = New code ▲ = Revised code